Panbela Therapeutics, Inc.

Panbela reported Q3 2024 net loss of $7.2 million, or $1.48 per diluted share, versus a net loss of $7.8 million, or $53.74 per diluted share, in Q3 2023. General and administrative expenses were approximately $1.1 million, flat year over year, and research and development expenses were approximately $6.1 million versus $6.7 million a year ago, helped by lower preclinical costs and lower CRO spend for ASPIRE. Cash as of September 30, 2024 was approximately $142,000, total current assets were $5.2 million, current liabilities were $20.1 million, and cash used in operations for the nine months ended September 30, 2024 was approximately $12.5 million. Management said the company secured a $12 million Nant Capital note package, with a $2.85 million Tranche A already funded and a $9.15 million Tranche B expected by November 15; the funds are for general corporate purposes and debt repayment. No formal revenue guidance was given, and the call did not provide next-quarter or full-year financial guidance beyond management’s comment that cash should last into the first quarter of next year.

Jennifer Simpson framed the quarter around strategic and clinical progress rather than near-term commercial metrics. She emphasized the Nant Capital relationship as more than financing, describing it as validation of Panbela’s polyamine-pathway approach and potential synergy with ImmunityBio’s immune-cell activation technology. Her tone was upbeat on the pipeline, especially ASPIRE, where she highlighted a faster-than-expected enrollment pace and a lower-than-expected event rate as potentially meaningful signs for efficacy.

Sue Horvath focused on expenses, liquidity, and the structure of the Nant financing. She said G&A was about $1.1 million and R&D was about $6.1 million in Q3, with lower R&D driven by reduced preclinical costs and lower direct CRO costs for ASPIRE. She also noted cash of only about $142,000 at quarter-end, current liabilities of $20.1 million, nine-month cash used in operations of about $12.5 million, and that the Nant notes carry six-month maturity, SOFR+8% interest, and conversion at $0.37 per share with a 33.33% ownership cap until maturity.

The main analyst question centered on whether the Nant financing improves Panbela’s chances of an equity uplist or simply extends runway. Management said it does not immediately help with stockholders’ equity requirements because it is a loan, and that discussing anything beyond that would be speculation. In a follow-up, Sue Horvath said there are no requirements for the second tranche and that the company expects to continue managing cash closely so it lasts into the first quarter of next year.